| Date Filed | Type | Description |
| 07/14/2020 |
8-K
| Quarterly results |
| 06/12/2020 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/30/2020 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/21/2020 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...|
Docs:
|
"Novelion Therapeutics Confirms Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. today announced that the implementation of the Company’ s voluntary liquidation commenced at 5:00 p.m. Pacific Time today, January 16, 2020 . As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator and charged with overseeing all aspects of the Liquidation. Concurrent with the Liquidator’ s appointment: Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company. Shareholders and other interested parties should visit www.alvarezandmarsal.com/n..." |
|
| 01/21/2020 |
SC 13G/A
| NB Public Equity K/S reports a 9% stake in Novelion Therapeutics Inc. |
| 01/15/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/15/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2020 |
SC 13G/A
| EdgePoint Investment Group Inc. reports a 18.7% stake in NOVELION THERAPEUTICS INC. |
| 01/03/2020 |
8-K
| Quarterly results |
| 12/17/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/12/2019 |
4
| STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Bought 5,202 shares
@ $0.6916, valued at
$3.6k
Bought 40 shares
@ $0.69, valued at
$27.6
Bought 1,000 shares
@ $0.7, valued at
$700 |
|
| 12/11/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/09/2019 |
4
| STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Bought 5,160 shares
@ $0.7, valued at
$3.6k
Bought 40 shares
@ $0.7, valued at
$28
Bought 4,500 shares
@ $0.7, valued at
$3.2k
|
|
| 11/26/2019 |
4
| STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Bought 89,845 shares
@ $0.7461, valued at
$67k
|
|
| 11/15/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 11/05/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 10/16/2019 |
4
| STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Bought 100,000 shares
@ $0.649, valued at
$64.9k
|
|
| 10/08/2019 |
8-K
| Quarterly results |
| 10/08/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/03/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/03/2019 |
8-K
| Quarterly results |
| 10/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/02/2019 |
3
| STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 3 on NOVELION THERAPEUTICS INC. |
| 10/02/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/27/2019 |
SC 13D/A
| Whitefort Capital Master Fund, LP reports a 1.5% stake in Novelion Therapeutics Inc. |
| 09/27/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 09/26/2019 |
4
| PRICE MICHAEL DENNIS (CFO) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Paid exercise price by delivering 3,926 shares
@ $0.76, valued at
$3k
|
|
| 09/26/2019 |
4
| Chan Barbara Y (See Remarks) has filed a Form 4 on NOVELION THERAPEUTICS INC.|
Txns:
| Paid exercise price by delivering 1,688 shares
@ $0.76, valued at
$1.3k
|
|
| 09/25/2019 |
8-K
| Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; E... |
| 09/25/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/20/2019 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/20/2019 |
SC 13D/A
| Healthcare Value Capital, LLC reports a 7.4% stake in Novelion Therapeutics Inc. |
|